
Dengue vaccine
In 2024, dengue fever is expected to surge to three times the 5-year average.
Today - April 30, 2024
In 2024, it is expected that
dengue fever will have an outbreak higher than the average
of the past 5 years by up to 3 times
New tetravalent dengue vaccine
Can be administered from ages 4–60 years
Vaccine effectiveness
Prevents dengue fever from all 4 serotypes: 80.2%
Reduces hospitalization rate by 90.4%
Vaccine administration recommendations
Can be administered to both people who have and have not previously been infected, without needing a prior blood test
Without having to do a blood test
No underlying disease with low immunity
*Information from: Epidemiology Division / Risk Communication Bureau, Department of Disease Control
Date: 10 January 2024
**Vaccine effectiveness is based on patients without underlying diseases with low immunity
dengue fever will have an outbreak higher than the average
of the past 5 years by up to 3 times
New tetravalent dengue vaccine
Can be administered from ages 4–60 years
Vaccine effectiveness
Prevents dengue fever from all 4 serotypes: 80.2%
Reduces hospitalization rate by 90.4%
Vaccine administration recommendations
Can be administered to both people who have and have not previously been infected, without needing a prior blood test
Without having to do a blood test
No underlying disease with low immunity
*Information from: Epidemiology Division / Risk Communication Bureau, Department of Disease Control
Date: 10 January 2024
**Vaccine effectiveness is based on patients without underlying diseases with low immunity












